Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;3(6):665-680.
doi: 10.1038/s43018-022-00401-1. Epub 2022 Jun 28.

Charting roadmaps towards novel and safe synergistic immunotherapy combinations

Miguel F Sanmamed  1   2   3   4 , Pedro Berraondo  1   2   4 , Maria E Rodriguez-Ruiz  1   2   3 , Ignacio Melero  5   6   7   8
Affiliations
Review

Charting roadmaps towards novel and safe synergistic immunotherapy combinations

Miguel F Sanmamed et al. Nat Cancer. 2022 Jun.

Abstract

Checkpoint inhibitor-based cancer immunotherapy is often combined in the clinic with other immunotherapy strategies, targeted therapies, chemotherapy or standard-of-care treatments to achieve superior therapeutic efficacy. The large number of immunotherapy combinations that are currently undergoing clinical testing necessitate the establishment of faithful criteria to prioritize optimal combinations with evidence of synergy, to determine their safety and optimal sequence of administration and to identify biomarkers of therapy resistance and response. In this review, we focus on recent developments in immunotherapy combinations and reflect on how combinations should be optimized to maximize the impact of immunotherapy in clinical oncology.

PubMed Disclaimer

References

    1. Gulick, R. M. et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350, 1850–1861 (2004). - PubMed - DOI
    1. Lawn, S. D. & Zumla, A. I. Tuberculosis. Lancet 378, 57–72 (2011). - PubMed - DOI
    1. Falzone, L., Salomone, S. & Libra, M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018). - PubMed - PMC - DOI
    1. Devita, V. T., Serpick, A. A. & Carbone, P. P. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann. Intern. Med. 73, 881–895 (1970). - PubMed - DOI
    1. Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372–8377 (2003). - PubMed - PMC - DOI

Publication types

Substances

LinkOut - more resources